Cargando…

Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome

INTRODUCTION: Rituximab (RTX) effectively prevents relapses in patients with complicated steroid-sensitive nephrotic syndrome (SSNS). The 1-year relapse-free survival rate is approximately 30% in children after the first episode of SSNS treated with standardised corticosteroids. Whether the benefits...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jialu, Shen, Qian, Xie, Li, Wang, Jiyang, Li, Yaxuan, Chen, Jing, Fang, Xiaoyan, Tang, Xiaoshan, Qian, Biyun, Xu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562314/
https://www.ncbi.nlm.nih.gov/pubmed/36223961
http://dx.doi.org/10.1136/bmjopen-2022-064216